Date:
Wed, 05 Aug 2026 13:40:09 EDT
Content:
The U.S. Food and Drug Administration (FDA) has issued an update concerning Sentiss Pharma Pvt. Ltd., located in Himachal Pradesh, India. This announcement provides oversight details regarding the facility’s manufacturing standards and regulatory status.
The update references the facility’s compliance history and identification under FEI number 3008250236. As a global provider of pharmaceutical products, Sentiss Pharma is subject to periodic inspections to ensure that their production processes meet strict safety and quality regulations required for the U.S. market.
The FDA remains committed to monitoring international drug manufacturers to safeguard the public. Ensuring that all imported medications are produced under current good manufacturing practices (CGMP) is a critical component of the agency’s mission to maintain a safe and reliable drug supply chain.
Source: U.S. Food and Drug Administration
Link:
http://www.fda.gov/about-fda/sentiss-pharma-pvt-ltd
Keywords:
FDA, Sentiss Pharma, pharmaceutical manufacturing, India, drug safety, Himachal Pradesh